J Neuropsychiatry Clin Neurosci
August 2021
Patients with Parkinson's disease (PD) commonly have speech and voice problems that affect their functional communication and that are not sensitive to pharmacological or neurosurgical treatments. The authors aimed to evaluate the effects of speech and language therapies (SLTs) on dysphonia in patients with PD by analyzing data from published randomized controlled trials (RCTs). Studies in English and Chinese that were related to speech and language treatment for patients with PD were retrieved from PubMed, Embase, Chinese National Knowledge Infrastructure, China Science and Technology Journal Database, Chinese Biomedical Literature Database, and Wanfang Database.
View Article and Find Full Text PDFBackground: Exosomal miRNA expression for myasthenia gravis (MG) has not been studied.
Methods: Plasma samples from 92 patients with MG and 49 age-matched healthy controls (HCs) were screened (by means of deep sequencing and quantitative real-time polymerase chain reaction) for differentially expressed exosomal microRNA (miRNAs). miR-106a-5p was chosen to further verify because it is reportedly involved in MG pathogenesis.